Drugs / HIVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01428596 | Sep 2010 → Dec 2020 | HIV infectious disease | GeneCure Biotechnologies | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01428596 ↗ |
| Modality | Vaccine | “a replication-defective HIV-1 vaccine (HIVAX)” NCT01428596 ↗ |
| Route | Subcutaneous | “given as a subcutaneous injection to HIV-1 infected participants” PMID 27002500 ↗ Mar 2016 |